Wednesday, October 4, 2023
The incidence of venous thromboembolism (VTE) is steadily increasing and is projected to affect 2 million adults in the United States by 2050. With several treatment options and patient factors to consider, it can be challenging to tailor VTE treatment. This collection focuses on identifying patients at risk, appropriate use of direct oral anticoagulants (DOACs), and strategies for VTE prophylaxis within the hospital setting and for the extended post-discharge period.
Supported by an independent educational grant from
Portola Pharmaceuticals, Inc.
See All
See All
Review strategies and tools available for appropriate VTE prophylaxis and techniques to manage major bleeding in acutely medically ill patients.
Download
See All
Steering Committee Chair
Consultant Physician, Department of Haematological Medicine, Guys and St. Thomas' NHS Foundation Trust, King's College London, London, United Kingdom
Professor; Chair of the Department of Emergency Medicine, UT Southwestern Medical Center, Dallas, Texas
Professor, University of Washington, Seattle Washington
Clinical Assistant Professor of Pharmacy; Cardiac Critical Care Pharmacist, Presbyterian Healthcare Services, University of New Mexico College of Pharmacy, Albuquerque, New Mexico
Professor of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota
Assistant Professor of Medicine, Harvard Medical School; Director of General Cardiology, Cardiovascular Division, Brigham and Women's Hospital, TIMI Study Group, Boston, Massachusetts
Steering Committee Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; ACI Clinical (Applied Clinical Intelligence LLC); Aspen Pharmacare; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Boston Scientific; CSL Behring; Daiichi Sankyo, Inc.; GlaxoSmithKline; GLG Pharma, LLC; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Leo Pharma; Ono Pharma USA Inc, Pfizer Inc.; Portola Pharmaceuticals, Inc.; Sanofi; Takeda Pharmaceuticals North America, Inc.; TRN Pharma Private Limited;
Served as a speaker or a member of a speakers bureau for: Aspen Pharmacare; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pfizer Inc.; Portola Pharmaceuticals, Inc.;
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: ET Healthcare Inc.; Janssen Pharmaceuticals; Roche Holding AG
Received grants for clinical research from: Novartis Pharmaceuticals Corporation; Ortho Clinical Diagnostics; Roche Holding AG; Stago
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Janssen Pharmaceuticals
Received grants for clinical research from: Daiichi Sankyo, Inc.; Incyte Corporation
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Janssen Pharmaceuticals; Portola Pharmaceuticals, Inc.
Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; Janssen Pharmaceuticals; Pfizer Inc.; Portola Pharmaceuticals, Inc.
Has closed no relevant financial relationships.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; Portola Pharmaceuticals, Inc.
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.